Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Metabolyz

Claya
Graded #264

Higher grade

vs+3.1999999999999957
Metabolyz
Graded #339

Lower grade

The verdict

Claya takes it — 62.8/100 to 59.6/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMetabolyz +3
42
45
Dose & formulationClaya +35
75
40
Clinical oversightClaya +1
82
81
Labs & monitoringMetabolyz +10
53
63
FulfillmentMetabolyz +19
67
86
Contract termsClaya +6
61
55
Claya · left barMetabolyz · right bar

The numbers

MetricClayaMetabolyz
WeighScore62.8/10059.6/100
GradeCC
Scorecard rank#264#339
Semaglutide$299/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #264 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Metabolyz

Graded #339 · C

Strengths

  • Three GLP-1 programs: standard semaglutide, dual-agonist tirzepatide, and a microdose protocol for near-goal or dose-sensitive patients
  • Nutrition, movement, and lifestyle coaching included in all programs at no extra charge
  • Medication compounded in licensed 503A/503B US pharmacies with temperature-controlled, unmarked direct-to-door delivery
  • Licensed provider supervision with direct messaging access and structured check-ins throughout
  • Telehealth across all 50 states; BMI 27+ eligibility (25+ with weight-related condition)

Where it loses points

  • Pricing is fully gated — not disclosed until after consultation, preventing upfront cost comparison
  • Compounded GLP-1 only — no brand-name options (Wegovy, Zepbound) available
  • No LegitScript certification or named medical leadership found on public-facing pages
  • Labs not mentioned as included — unclear whether baseline or follow-up bloodwork is offered
  • Newer brand with no external reviews, published outcomes data, or notable accreditations

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard